A revolution in the treatment of aggressive liposarcoma by pazopanib combined with chemotherapy- A case report
-
Published:2019-05-31
Issue:5
Volume:6
Page:3180-3183
-
ISSN:2198-4093
-
Container-title:Biomedical Research and Therapy
-
language:
-
Short-container-title:Biomed. Res. Ther.
Author:
Payandeh Mehrdad,Karami Afshin,Rahimi Samira,Karami Noorodin
Abstract
Pazopanib is a new tyrosine kinase inhibitor which acts as anti-VEGF signaling and antiangiogenesis. In some countries, this drug has been approved for the treatment of advanced, or metastatic soft tissue sarcoma. Nevertheless, the efficacy of Pazopanib has not yet been proven in patients with advanced liposarcoma. We reported a rare case of advanced liposarcoma that after several courses of chemotherapy, the disease was relapsed, and CT-scan results showed lung metastasis. Therapeutic measures, including surgery and chemotherapy with pazopanib, were successful in destroying the metastatic mass in the patient's lung. Our finding provides a new therapeutic approach for pleomorphic liposarcoma.
Publisher
Biomedical Research and Therapy
Subject
General Biochemistry, Genetics and Molecular Biology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献